Direct comparison of Tezepelumab and Dupilumab in CRSwNP in a real world setting
This study is looking at two existing medicines, Dupixent and Tezspire, that are used to treat a long-term condition called Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). This condition causes swelling, mucus, and growths (polyps) inside the nose and sinuses. This is a 'real-world' study, meaning it's observing how these medicines work in people who are already using them in their daily lives, rather than in a strict laboratory setting. The main goal is to find out which medicine helps more with symptoms like nasal blockage, sense of smell, and overall quality of life over a year. The study is particularly interested in how these treatments affect nose symptom scores and impact daily living.
At a glance
What is this study about?
This research study is called a 'real-world' study, which means doctors are observing people who are already taking specific medicines as part of their regular treatment, rather than inviting new people into a controlled trial. The focus here is on two medicines, Dupixent and Tezspire, both of which are used to treat a long-term condition called Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). This condition causes ongoing inflammation in the nose and sinuses, often leading to symptoms like a blocked or runny nose, reduced sense of smell, and growths called nasal polyps.
The main aim of this study is to compare these two medicines to see which one works better in improving people's symptoms and their overall quality of life over a year. Researchers will be looking at how bothersome participants' nose symptoms are (using a numerical score) and how much the condition affects their daily life, including their general well-being. They want to understand the practical differences between these treatments when used by people in their everyday routines.
By gathering this information, doctors hope to gain a clearer picture of how effective Dupixent and Tezspire are in managing CRSwNP in a real-life setting. This will help them make more informed decisions about which treatment might be best for different patients in the future, ultimately improving care for people living with this chronic condition.
Key takeaways
- Compares two existing medicines, Dupixent and Tezspire, for nasal polyps.
- Studies how these medicines work in 'real-world' daily use.
- Aims to understand which medicine improves symptoms and quality of life most over one year.
- Participants will already be taking one of these medicines.
- Involves tracking symptoms, smell, and general wellbeing for 12 months.
- Helps doctors choose the best treatment for future patients.
Who may be eligible?
To be able to take part in this study, you need to be an adult, aged 18 years or older. There is no upper age limit for participating.
This study includes both men and women. The specific eligibility for this *real-world* study means that participants are likely already receiving treatment with either Dupixent or Tezspire for their Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) as part of their standard medical care. This isn't a study where you try a new medicine; rather, it observes how existing treatments are working for you.
- Are you 18 years old or older?
- Do you have Chronic Rhinosinusitis with Nasal Polyps?
- Are you currently being treated with either Dupixent (Dupilumab) or Tezspire (Tezepelumab)?
- Are you able to attend follow-up appointments over a 12-month period?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you take part in this study, you will continue with your regular treatment of either Dupixent or Tezspire, as prescribed by your doctor. The study will involve monitoring your symptoms and overall health over a 12-month period. You'll likely be asked to complete questionnaires about your nose symptoms, your sense of smell, and how your condition affects your daily life. Doctors will also track some physical measurements related to your nose and breathing. These assessments will typically happen at the beginning of the study and again after 12 months, with some checks possibly in between. You might also be asked about any side effects you experience. The total duration of your active involvement in the study, where your progress is being monitored, will be one year.
Potential risks and benefits
Locations (1)
- —Austria
Common questions
What is Chronic Rhinosinusitis with Nasal Polyps?
It's a long-term condition causing inflammation in your nose and sinuses, often leading to stuffy nose, mucus, and growths called nasal polyps.
Are the medicines being tested new?
No, Dupixent and Tezspire are existing medicines already used to treat this condition. This study is comparing how well they work in a real-world setting.
Do I have to stop my current treatment if I join?
No, you would continue taking your prescribed medicine (either Dupixent or Tezspire) as usual. This study observes your ongoing treatment.
What kind of information will the study collect about me?
Researchers will look at your nose symptom scores, how your sense of smell changes, your general quality of life, and any side effects you experience.
How long will I be involved in the study?
The main part of your participation, where your progress is monitored, will last for 12 months.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.